(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. (Q52985772)

10 May 2018

title

(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. (English)

1 reference

10 May 2018

Antonia Dimitrakopoulou-Strauss

author

7

1 reference

10 May 2018

Boris Hadaschik

object named as

B A Hadaschik

5

0 references

author name string

C Sachpekidis

1

1 reference

10 May 2018

M Eder

2

1 reference

10 May 2018

K Kopka

3

1 reference

10 May 2018

W Mier

4

1 reference

10 May 2018

U Haberkorn

6

1 reference

10 May 2018

publication date

12 January 2016

1 reference

10 May 2018

number of pages

12

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

10 May 2018

volume

43

1 reference

10 May 2018

issue

7

1 reference

10 May 2018

page(s)

1288-1299

1 reference

10 May 2018

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Management of recurrent disease after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Radionuclide and hybrid imaging of recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Fluorocholine PET/CT in patients with prostate cancer: initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Prostate biopsy guided by 18F-fluorocholine PET in men with persistently elevated PSA levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Prostate-specific membrane antigen-based imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

PSMA as a target for radiolabelled small molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

A JAVA environment for medical image data analysis: initial application for brain PET quantitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Determination of 18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Pharmacokinetic studies of ⁶⁸Ga-labeled Bombesin (⁶⁸Ga-BZH₃) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

The quantification with FDG as seen by a physician

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Quantitative analysis and parametric imaging of 18F-labeled monomeric and dimeric RGD peptides using compartment model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Circulating tumour cells-monitoring treatment response in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-015-3302-4

Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis

21 January 2018

1 reference

12 December 2020

Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

1 reference

12 December 2020

Requirements and implementation of a flexible kinetic modeling tool

1 reference

12 December 2020

Prostate-specific membrane antigen expression in normal and malignant human tissues

1 reference

12 December 2020

Basic principles and applications of fractal geometry in pathology: a review

1 reference

12 December 2020

The applications of PET in clinical oncology

1 reference

12 December 2020

Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation

1 reference

12 December 2020

Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy

1 reference

12 December 2020

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy

1 reference

12 December 2020

Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.

1 reference

12 December 2020

Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.

1 reference

12 December 2020

Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs

1 reference

12 December 2020

PET/CT studies of multiple myeloma using 18 F-FDG and 18 F-NaF: comparison of distribution patterns and tracers’ pharmacokinetics

1 reference

12 December 2020

Correlation of pathologic findings with progression after radical retropubic prostatectomy

1 reference

12 December 2020

Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy

1 reference

12 December 2020

10.1007/S00259-015-3302-4

Identifiers

DOI

1 reference

10 May 2018

1 reference

10 May 2018